Institution Directory

Clinical trials at UPMC (University of Pittsburgh)

Sites in Pittsburgh, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1598

Shown on this page

Current sort

Live official records

Conditions: Obstructive Sleep Apnea, Comorbid Insomnia and Sleep Apnea, Insomnia
Interventions: Digital Cognitive Behavioral Therapy (CBT-i)-COAST; Device
Lead sponsor: Thomas Kaffenberger; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cerebellar Stroke, Autoimmune Cerebellar Disorders
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: George Wittenberg; Other
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Optic Neuritis, Myelitis, Myelitis, Transverse
Interventions: High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions: Paradise Renal Denervation System, Renal Angiogram; Device · Procedure
Lead sponsor: ReCor Medical, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more

Conditions: Spina Bifida, Neurogenic Bowel, Bowel Incontinence
Interventions: Retrograde Enema, Antegrade Enema; Procedure
Lead sponsor: David Chu; Other
Eligibility: 5 Years and older
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Aortic Stenosis
Interventions: Medtronic TAV, Edwards TAV; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Refractory Differentiated Thyroid Gland Carcinoma
Interventions: Biospecimen Collection, Cabozantinib, Computed Tomography, Dabrafenib, Magnetic Resonance Imaging, Questionnaire Administration, Trametinib; Procedure · Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 307
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 222 more

Conditions: Pancreatic Adenocarcinoma
Interventions: Retifanlimab, Chemotherapy, 9-ING-41; Drug
Lead sponsor: Anwaar Saeed; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Fabry Disease
Interventions: AMT-191; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
Interventions: Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 25 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 13
States / cities: Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more

Conditions: Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Interventions: Atezolizumab, Biospecimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Tocilizumab; Biological · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 110
States / cities: Anaheim, California • Bellflower, California • Los Angeles, California + 89 more

About this UPMC (University of Pittsburgh) institution page

What this page lists: ClinicalTrials.gov records that list UPMC (University of Pittsburgh) in Pittsburgh, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UPMC (University of Pittsburgh)

Filter and sort this campus

Live official records

Does the Timing of Insomnia Therapy (CBT-i) Impact the Usage and Compliance of Upper Airway Stimulation (UAS) Treatment of Obstructive Sleep Apnea (OSA)

Brain Stimulation to Improvement After Cerebellar Damage

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

Bowel Continence Across the Lifespan in People With Spina Bifida

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

About this UPMC (University of Pittsburgh) institution page